Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aprepitant - George Washington University/Hoth Therapeutics

Next Previous
X
Search
Drug Profile

Aprepitant - George Washington University/Hoth Therapeutics

Alternative Names: HT-001; WEG-232

Latest Information Update: 12 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The George Washington University
  • Developer Hoth Therapeutics; The George Washington University
  • Class Anti-inflammatories; Antidepressants; Antiemetics; Antineoplastics; Antitussives; Antivirals; Fluorobenzenes; Ketones; Morpholines; Skin disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists; Peptide hydrolase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Skin disorders
  • No development reported Cardiovascular disorders; Metabolic disorders; Neurogenic inflammation

Most Recent Events

  • 05 Sep 2024 Efficacy and adverse events data from a phase IIa CLEER trial in Skin disorders released by Hoth Therapeutics
  • 18 Jan 2024 Hoth Therapeutics receives US FDA approval for protocol amendments in phase IIa trial for Skin disorders (Chemotherapy-induced) (Topical)
  • 27 Dec 2023 Hoth Therapeutics receives approval from Washington University of St. Louis, MD Anderson Cancer Center and University of Miami for Aprepitant for phase-IIa trial in Skin disorders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top